KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Receivables (2016 - 2025)

Gsk has reported Receivables over the past 10 years, most recently at $11.5 billion for Q4 2025.

  • For Q4 2025, Receivables rose 16.1% year-over-year to $11.5 billion; the TTM value through Dec 2025 reached $11.5 billion, up 16.1%, while the annual FY2025 figure was $11.5 billion, 16.1% up from the prior year.
  • Receivables for Q4 2025 was $11.5 billion at Gsk, up from $9.9 billion in the prior quarter.
  • Over five years, Receivables peaked at $12.3 billion in Q4 2021 and troughed at $9.7 billion in Q4 2022.
  • A 5-year average of $10.8 billion and a median of $10.5 billion in 2023 define the central range for Receivables.
  • Biggest five-year swings in Receivables: grew 16.91% in 2021 and later fell 21.06% in 2022.
  • Year by year, Receivables stood at $12.3 billion in 2021, then dropped by 21.06% to $9.7 billion in 2022, then rose by 7.75% to $10.5 billion in 2023, then decreased by 5.63% to $9.9 billion in 2024, then increased by 16.1% to $11.5 billion in 2025.
  • Business Quant data shows Receivables for GSK at $11.5 billion in Q4 2025, $9.9 billion in Q4 2024, and $10.5 billion in Q4 2023.